Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06373731 · ClinicalTrials.gov registry record · Phase 3
ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)
A Phase 3 study of Age Related Macular Degeneration (ARMD), sponsored by Stealth BioTherapeutics.
- Active
- Registry status
- Phase 3
- Development phase
- 313
- Enrollment target
- 20
- Study locations
NCT06373731 is a Phase 3 study of Age Related Macular Degeneration (ARMD) that is active but no longer recruiting, run by Stealth BioTherapeutics. The registered enrollment target is 313 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT06373731, a Phase 3 study of Age Related Macular Degeneration (ARMD), is active but no longer recruiting, sponsored by Stealth BioTherapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 313 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical trial is to evaluate the efficacy, safety and pharmacokinetics of elamipretide in subjects with dry age-related macular degeneration (AMD). The main questions it aims to answer are: what is the rate of change in the macular area of photoreceptor loss in subjects who receive a daily dose of elamipretide compared with those who receive a look-alike substance that contains no active drug, and what is the safety and tolerability of elamipretide daily subcutaneous injections. Participants will receive either once daily subcutaneous doses of 40mg elamipretide or placebo and the two treatment groups will be compared.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Elamipretide
Study Locations (20)
California
- Retina Associates of Southern California - Huntington Beach
- Retina Consultants of San Diego - Poway
- Retinal Consultants Medical Group - Sacramento
- Orange County Retinal Medical Group - Santa Ana
- Bay Area Retina Associates - Walnut Creek
Florida
- Vitreo Retinal Associates - Gainesville
- Florida Retina Institute - Orlando
- Retina Vitreous Associates of Florida - St. Petersburg
Arizona
- Associated Retina Consultants - Phoenix
- Barnet Dulaney Perkins Eye Center - Sun City
New Jersey
- Mid Atlantic Retina - Cherry Hill
- NJ Retina - Teaneck
Colorado
- Retina Consultants of Southern Colorado - Colorado Springs
Connecticut
- Connecticut Eye Consultants, P.C. - Danbury
Illinois
- University Retina and Macula Associates - Oak Forest
Indiana
- Associated Vitreoretinal and Uveitis Consultants - Carmel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 313 participants |
| Start Date | 2024-05-30 |
| Est. Completion | 2027-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06373731
The ClinicalTrials.gov registry entry for NCT06373731 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 313 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stealth BioTherapeutics, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Age Related Macular Degeneration (ARMD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06373731 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06373731 about?
NCT06373731 is a clinical study titled "ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)". The goal of this clinical trial is to evaluate the efficacy, safety and pharmacokinetics of elamipretide in subjects with dry age-related macular degeneration (AMD). The main questions it aims to answer are: what is the rate of change in the macular area of photoreceptor loss in subjects who receive...
What is the current status of trial NCT06373731?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 313 participants. The study started on 2024-05-30. Estimated completion is 2027-09.
What conditions does trial NCT06373731 study?
This clinical trial studies the following conditions: Age Related Macular Degeneration (ARMD).
What interventions are being tested in trial NCT06373731?
The interventions under investigation include: Placebo (DRUG), Elamipretide (DRUG).
Who is sponsoring clinical trial NCT06373731?
This trial is sponsored by Stealth BioTherapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06373731 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age Related Macular Degeneration (ARMD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.